logo
Rural hospitals in the US are closing maternity wards, reducing medical access

Rural hospitals in the US are closing maternity wards, reducing medical access

The Star12-06-2025
Rural hospitals across the United States are shuttering their labour and delivery units, leaving rural Americans with less access to necessary medical care.
Across the country since 2020, 101 rural hospitals have stopped delivering babies or announced they soon will, according to a recent report from the Center for Healthcare Quality & Payment Reform.
That includes three hospitals in Texas, bringing the state to a total of 93 rural hospitals that do not provide labour and delivery services. Across the state, well over half of rural hospitals do not deliver babies.
State organisations are sounding the alarm. The Rural Texas Maternal Health Assembly reported in November that 47% of Texas counties are "maternity care deserts." That's 14% higher than the national average, the assembly wrote.
Rural hospitals are a lifeline to their communities, which may be located many miles from the next nearest medical facility.
In medical emergencies, minutes matter – and long travel time leaves rural residents with lower odds of surviving.
"Travel burden is real, and geography of Texas can be very challenging," said John Henderson, the president and chief executive of the Texas Organization of Rural & Community Hospitals.
"That's okay for certain things. ... It's not okay if you're having a heart attack or a stroke or delivering a baby."
For some rural Texans, labour and delivery department closures could be the difference between life and death.
'Canary in the coal mine'
It's not just about maternal health – across the board, many rural hospitals are struggling financially.
Half of rural Texas hospitals are at risk of closure, according to the Center for Healthcare Quality & Payment Reform. For some hospitals, the threat has already become a reality.Mid Coast Medical Center Trinity, north of Houston, announced in April that it was closing before the end of the month.
"It kind of feels like a death in the family," Henderson said of the closure.
For a struggling rural hospital, closing the labour and delivery unit may be an alternative to closing the entire hospital.
That's in part because labour and delivery units can be costly to operate. They must be staffed around the clock, since births can't always be scheduled or sequestered to regular business hours.
In rural hospitals, which often have low patient volume, the unit could go long stretches without seeing any births at all.
"You're basically paying people to sit in the hospital waiting for births that are very unlikely to happen on the majority of days," said Harold Miller, the chief executive of the Center for Healthcare Quality & Payment Reform.
Labour and delivery is also not a required service – unlike other services such as emergency medical care - which makes those units more likely to be chopped.
"In some ways, it's the canary in the coal mine on these things," Miller said. "If they're in trouble, where are they going to look first? That's where they're going to look first."
Exacerbating maternal health issues
As an immediate impact of labour and delivery closures, rural residents are forced to drive further to access care.That travel time means worse outcomes for women who are pregnant or in labour, according to the assembly's November report.
"The lack of local services harms the health of mothers and babies," the Assembly wrote.
The impact of travel time means that "rurality in and of itself is a factor in the maternal health crisis," the assembly wrote.
Long travel time also exacerbates an existing problem: Texas as a whole already falls short on maternal health outcomes.
The state's infant mortality rate is about on par with the national average, according to data from The Commonwealth Fund. The maternal death rate, however, is 34.7 per 100,000 live births, the data shows, compared to the national average of 26.3 per 100,000 births.
Overall, the organisation ranked Texas as second to last in the country on women's health and reproductive care.
A 'long-term issue'
Advocates say there are potential solutions to rural hospitals' struggles.
Miller said the country as a whole should pay rural hospitals for their standby costs, so they can afford to keep the doors open no matter how many patients walk through.
In the meantime, he said, individual states and the federal government should take steps to protect rural hospitals. In his view, those efforts can't only be one-time grants or other short-term assistance.
"The problem is, this is a long-term issue," Miller said. "There has to be some stream of money that is adequate on an ongoing basis, year after year."
In Texas, Henderson pointed to a proposed bill from Representative Gary VanDeaver, R-New Boston. House Bill 18 aims to stabilize rural hospitals' and clinics' finances through grant programmes, training and a new state office focused on rural hospital finance.
"There are Texans who do not currently have access to hospitals and health care services that the majority of us take for granted," VanDeaver said at a public hearing for the bill in March. "We have the opportunity this session to change that."
House Bill 18 was passed by the Texas House in April and is now in the Senate.
Outside of legislation, Henderson said he sees promise in telemedicine.
In order to survive, he said, rural hospitals and advocates need to look at unconventional solutions.
"It's not going to get easier. Rural hospitals aren't going to be less vulnerable in the near term," Henderson said. "We need to be working on innovative projects and finding ways for them to work together better." – The Dallas Morning News/Tribune News Service
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nuna Selected by White House and CMS to Join Landmark Health Tech Ecosystem Initiative
Nuna Selected by White House and CMS to Join Landmark Health Tech Ecosystem Initiative

Malaysian Reserve

time3 days ago

  • Malaysian Reserve

Nuna Selected by White House and CMS to Join Landmark Health Tech Ecosystem Initiative

SAN FRANCISCO, Aug. 4, 2025 /PRNewswire/ — Nuna announced its selection to join the Centers for Medicare & Medicaid Services (CMS) Health Tech Ecosystem, a landmark public-private initiative designed to transform healthcare for Americans. The initiative was unveiled at a White House event on Wednesday by President Donald Trump, CMS Administrator Dr. Mehmet Oz, HHS Secretary Robert F. Kennedy Jr., and Amy Gleason, Acting Administrator of DOGE. The event was attended by a select group of healthcare leaders and innovators, including Nuna Founder and CEO, Jini Kim. As part of the ecosystem, Nuna will contribute its expertise to two cornerstone efforts: Conversational AI Assistance and Diabetes & Obesity Prevention and Management. 'We're honored to stand alongside CMS in this bold and necessary step forward in healthcare,' said Jini Kim. 'We believe health isn't just built in the hospital or clinic; it's forged in the small moments of our daily lives. That's why we created Nuna, a trusted digital companion to help people succeed on their health journey, one day at a time.' Nuna's pledge is centered on its AI-powered digital engagement platform. Nuna's app empowers patients to confidently manage their chronic conditions through a combination of 24/7 conversational support, motivating gamification, and direct linkage to their clinical care team. This integrated approach drives powerful results: 72% of users with uncontrolled hypertension achieve control and 73% remain active after six months. By connecting daily patient behavior to the clinical team, Nuna bridges a critical gap in today's healthcare landscape by enabling timely, proactive intervention by care teams for their patients. 'Nuna has been a game changer for patients struggling with chronic conditions,' said David Ansell, MD, of Rush University System for Health and a Nuna development partner. 'It extends care from the clinic to the home and its AI enhanced education engages patients in behavioral change that persists over time. The result being better blood pressure control and improved health behaviors. Early results suggest it can crack the code on chronic disease self-management by engaging people to attend to their health when they are in their homes. This type of tech innovation has great potential to transform primary and preventive care across the US.' About Nuna Nuna is a digital health company dedicated to transforming chronic care by empowering patients and their clinicians. Its AI-driven platform provides personalized, continuous support to help people manage their health and chronic conditions in the moments that matter most. Nuna partners with health systems and health plans to improve patient outcomes, enhance care team efficiency, and reduce the overall cost of care. For more information about Nuna's participation in the CMS Digital Health Ecosystem, visit or contact press@

#SHOWBIZ: Justin Timberlake reveals battle with 'relentlessly debilitating' Lyme disease
#SHOWBIZ: Justin Timberlake reveals battle with 'relentlessly debilitating' Lyme disease

New Straits Times

time6 days ago

  • New Straits Times

#SHOWBIZ: Justin Timberlake reveals battle with 'relentlessly debilitating' Lyme disease

NEW YORK CITY: Justin Timberlake has disclosed that he was diagnosed with Lyme disease, describing it as "relentlessly debilitating." The singer made the candid revelation in an Instagram post after the final show of his Forget Tomorrow tour in Turkey. The 44-year-old artiste said he had been silently dealing with health issues throughout the tour. "I've been battling some health issues and was diagnosed with Lyme disease. I'm sharing this to shed light on what I've been up against, and not for sympathy," he wrote. Lyme disease is a bacterial infection spread by tick bites that can cause symptoms such as nerve pain, extreme fatigue, and cognitive difficulties. Timberlake said the diagnosis explained the nerve pain and exhaustion he experienced while performing. Despite the challenges, the *NSYNC alum chose to continue with the tour. "The joy that performing brings me far outweighs the fleeting stress my body was feeling. I'm so glad I kept going," he said. Timberlake added that he chose to go public to avoid misunderstandings and to demonstrate his resilience. "I wanted to be transparent, so my struggles wouldn't be misinterpreted. I'm proud of my mental tenacity," he explained. The tour, which began in April 2024, spanned Europe, North America, and Asia. It received mixed reviews, with some critics noting underwhelming performances, which now make more sense in light of his health battle. Timberlake, who has sold over 88 million records and won ten Grammy Awards, is married to actress Jessica Biel, 42. They share two sons, Silas and Phineas. He joins other celebrities like Avril Lavigne and Bella Hadid who have also spoken out about their experiences with Lyme disease. The US public health agency, the Centers for Disease Control and Prevention, estimates that the illness affects nearly half a million Americans each year.

Trump pressures 17 pharma CEOs to cut US drug prices
Trump pressures 17 pharma CEOs to cut US drug prices

The Sun

time6 days ago

  • The Sun

Trump pressures 17 pharma CEOs to cut US drug prices

WASHINGTON: President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday. Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas. Trump sent the letters to the chief executives of Eli Lilly , Sanofi, Regeneron, Merck & Co , Johnson & Johnson, and AstraZeneca, among others, the White House said. 'Most proposals my Administration has received to 'resolve' this critical issue promised more of the same; shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry,' Trump wrote in the letters, copies of which were posted on his Truth Social account. Shares of Pfizer, Eli Lilly and Gilead Sciences closed down about 2% each, while the NYSE Arca Pharmaceutical Index fell 3% on Thursday. Trump called on drugmakers to provide so-called most-favored-nation prices to every patient enrolled in the government Medicaid health program for low-income people, and to guarantee such pricing for new drugs. The policy is aimed at cutting U.S. prescription drug prices to the lowest possible price paid by members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest economies. Trump also said companies must return excess overseas revenue from raising prices in other countries to offset lower prices in the U.S. to American patients and taxpayers through an agreement with the government. He is requiring drugmakers to stipulate they would not offer other developed nations better prices than what they offer the United States, and said his administration would provide ways to cut out middlemen and sell directly to patients, provided they do so at most-favored-nation prices. Trump gave companies until September 29 to respond with binding commitments to those terms. 'If you refuse to step up, we will deploy every tool in our arsenal to protect Americans from abusive drug pricing practices,' he warned. Analysts, lobbyists and drug pricing experts said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. 'I might expect them to try to determine if any of their current products might be made available via direct sales (one of the requests) at a lower price than currently available in the U.S.,' said Stacie Dusetzina, professor of health policy at Nashville's Vanderbilt University. UBS analyst Trung Huynh said Trump's letters were a repeat of earlier demands and played down any likely industry impact, calling it 'just another shot in the dark.' Trump has already pushed for voluntary changes and some companies have pledged to build new U.S. manufacturing plants. U.S. patients pay by far the most for prescription medicines, often nearly three times more than in other developed nations. The country also invests heavily in pharmaceutical research and development. Drugmakers have said drastic price cuts would stifle innovation. Pharmaceutical companies including Pfizer, Novartis , AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Pfizer is working closely with the Trump Administration and Congress to improve access and affordability for American patients, said spokeswoman Amy Rose. 'Our discussions have been productive,' she said-REUTERS

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store